ATE395101T1 - Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel - Google Patents

Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel

Info

Publication number
ATE395101T1
ATE395101T1 AT04727664T AT04727664T ATE395101T1 AT E395101 T1 ATE395101 T1 AT E395101T1 AT 04727664 T AT04727664 T AT 04727664T AT 04727664 T AT04727664 T AT 04727664T AT E395101 T1 ATE395101 T1 AT E395101T1
Authority
AT
Austria
Prior art keywords
polypeptides
proteins
pharmaceutical composition
polypeptide
protein
Prior art date
Application number
AT04727664T
Other languages
English (en)
Inventor
Moshe Baru
Lea Carmel-Goren
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Application granted granted Critical
Publication of ATE395101T1 publication Critical patent/ATE395101T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04727664T 2003-04-15 2004-04-15 Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel ATE395101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46270103P 2003-04-15 2003-04-15

Publications (1)

Publication Number Publication Date
ATE395101T1 true ATE395101T1 (de) 2008-05-15

Family

ID=33299976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727664T ATE395101T1 (de) 2003-04-15 2004-04-15 Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel

Country Status (15)

Country Link
US (1) US20070167359A1 (de)
EP (1) EP1633440B1 (de)
JP (1) JP2006523683A (de)
CN (1) CN1774281B (de)
AT (1) ATE395101T1 (de)
AU (1) AU2004229253B2 (de)
BR (1) BRPI0409424B8 (de)
CA (1) CA2522179C (de)
DE (1) DE602004013769D1 (de)
DK (1) DK1633440T3 (de)
ES (1) ES2307009T3 (de)
MX (1) MXPA05010926A (de)
PL (1) PL1633440T3 (de)
PT (1) PT1633440E (de)
WO (1) WO2004091723A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554161A1 (de) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518172D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518170D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
WO2021092580A1 (en) * 2019-11-07 2021-05-14 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
CN115521603B (zh) * 2021-06-24 2026-03-10 复旦大学 一种可原位相转变形成凝胶的组合物及其用途
US20240058419A1 (en) * 2022-08-22 2024-02-22 Buddhist Tzu Chi Medical Foundation Method for treating optic neuropathy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH0482839A (ja) * 1990-07-20 1992-03-16 Green Cross Corp:The 蛋白質類・脂質小体複合体
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
ATE203415T1 (de) * 1994-02-08 2001-08-15 Amgen Inc Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
AU747391B2 (en) * 1998-04-27 2002-05-16 Cantab Biopharmaceuticals Patents Limited Pharmaceutical composition comprising factor VIII and neutral liposomes
RU2250911C2 (ru) * 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
WO2001060392A1 (en) * 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Oral, nasal and pulmonary dosage formualtions of copolymer 1
WO2002086117A1 (en) * 2001-04-20 2002-10-31 The University Of Vermont Compositions and methods to control bleeding
CA2478066C (en) * 2001-12-04 2009-09-08 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting

Also Published As

Publication number Publication date
WO2004091723A1 (en) 2004-10-28
US20070167359A1 (en) 2007-07-19
JP2006523683A (ja) 2006-10-19
CN1774281B (zh) 2010-10-13
BRPI0409424B8 (pt) 2021-05-25
EP1633440A1 (de) 2006-03-15
AU2004229253B2 (en) 2009-11-05
ES2307009T3 (es) 2008-11-16
EP1633440B1 (de) 2008-05-14
BRPI0409424B1 (pt) 2018-05-02
PT1633440E (pt) 2008-08-25
DE602004013769D1 (de) 2008-06-26
CA2522179A1 (en) 2004-10-28
BRPI0409424A (pt) 2006-04-25
AU2004229253A1 (en) 2004-10-28
PL1633440T3 (pl) 2008-12-31
CA2522179C (en) 2012-02-14
CN1774281A (zh) 2006-05-17
MXPA05010926A (es) 2005-11-25
DK1633440T3 (da) 2008-09-08

Similar Documents

Publication Publication Date Title
Goissis et al. Biocompatibility studies of anionic collagen membranes with different degree of glutaraldehyde cross-linking
ATE397626T1 (de) Rgd-angereicherte gelatine-ähnliche proteine mit verstärkter zellbindung
ATE283034T1 (de) Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
EP1778842B8 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
IL109403A0 (en) Oral drug delivery compositions and methods
CA2499014A1 (en) Lactoferrin compositions and methods of wound treatment
ATE206308T1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
DE69434980D1 (de) Stabile bakterizide Proteine, welche die Permeabilität erhöhen und pharmazeutische Zusammensetzungen, diese enthaltend
ATE187740T1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
ATE395101T1 (de) Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate
CA2071757A1 (en) Implant compositions containing a biologically active protein, peptide or polypeptide
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
MXPA05008785A (es) Esteres de polietilen glicol activados.
ATE467421T1 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
EP2329832A1 (de) Proteinzusammensetzung
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
Ali et al. Marine collagen: promising biomaterial in delivery of therapeutics for cancer therapy
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
Dey et al. Versatility of Collagen as a Natural Biopolymer for Biomedical, Food, and Cosmetic Applications
EP1862170A1 (de) Proteinformulierung
ATE452139T1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1633440

Country of ref document: EP

REN Ceased due to non-payment of the annual fee